UPCC 45418: An Open-Label Phase I/II Safety and Efficacy Study of Itacitinib in Combination with Everolimus in Subjects with Relapsed/Refractory Classical Hodgkin Lymphoma

Enrolling By Invitation
99 years or below
All
Phase 2
23 participants needed

Brief description of study

The study will assess how safe and well-tolerated a combination of the study drugs itacitinib and everolimus in patients with Hodgkin lymphoma. We also hope to learn how effective this experimental combination is in treating Hodgkin lymphoma, when given together.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: lymphoma
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 831774
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu

 

Interested in the study?

Message For Enrolling By Invitation Trial

study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact a study center.